JP2013514308A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013514308A5 JP2013514308A5 JP2012543701A JP2012543701A JP2013514308A5 JP 2013514308 A5 JP2013514308 A5 JP 2013514308A5 JP 2012543701 A JP2012543701 A JP 2012543701A JP 2012543701 A JP2012543701 A JP 2012543701A JP 2013514308 A5 JP2013514308 A5 JP 2013514308A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- ethyl
- oxadiazol
- tetrazol
- methoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 pyrazol-4-yl Chemical group 0.000 claims 253
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 34
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 31
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 31
- 150000001875 compounds Chemical class 0.000 claims 26
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 16
- 229910052731 fluorine Inorganic materials 0.000 claims 10
- 239000011737 fluorine Substances 0.000 claims 10
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 8
- 230000001154 acute effect Effects 0.000 claims 6
- 230000001684 chronic effect Effects 0.000 claims 6
- 125000001153 fluoro group Chemical group F* 0.000 claims 6
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 208000023504 respiratory system disease Diseases 0.000 claims 6
- 239000002671 adjuvant Substances 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 4
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims 4
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 4
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- FNKQXYHWGSIFBK-RPDRRWSUSA-N sapropterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 claims 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 3
- 125000005530 alkylenedioxy group Chemical group 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000001359 1,2,3-triazol-4-yl group Chemical group [H]N1N=NC([*])=C1[H] 0.000 claims 2
- 125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 claims 2
- 125000004505 1,2,4-oxadiazol-5-yl group Chemical group O1N=CN=C1* 0.000 claims 2
- 125000001305 1,2,4-triazol-3-yl group Chemical group [H]N1N=C([*])N=C1[H] 0.000 claims 2
- 125000004509 1,3,4-oxadiazol-2-yl group Chemical group O1C(=NN=C1)* 0.000 claims 2
- 229940124125 5 Lipoxygenase inhibitor Drugs 0.000 claims 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 2
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 2
- 229940118365 Endothelin receptor antagonist Drugs 0.000 claims 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 2
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 claims 2
- 229930003316 Vitamin D Natural products 0.000 claims 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 2
- 239000000048 adrenergic agonist Substances 0.000 claims 2
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 229940088710 antibiotic agent Drugs 0.000 claims 2
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 claims 2
- 239000003146 anticoagulant agent Substances 0.000 claims 2
- 229940127219 anticoagulant drug Drugs 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 239000002876 beta blocker Substances 0.000 claims 2
- 229940097320 beta blocking agent Drugs 0.000 claims 2
- 239000000480 calcium channel blocker Substances 0.000 claims 2
- 239000000812 cholinergic antagonist Substances 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 229960001334 corticosteroids Drugs 0.000 claims 2
- 229940082657 digitalis glycosides Drugs 0.000 claims 2
- 230000006806 disease prevention Effects 0.000 claims 2
- 239000002934 diuretic Substances 0.000 claims 2
- 229940030606 diuretics Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 2
- 229960001123 epoprostenol Drugs 0.000 claims 2
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 claims 2
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims 2
- 239000003119 guanylate cyclase activator Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical group 0.000 claims 2
- 239000000938 histamine H1 antagonist Substances 0.000 claims 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 2
- 230000036039 immunity Effects 0.000 claims 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 claims 2
- 125000004498 isoxazol-4-yl group Chemical group O1N=CC(=C1)* 0.000 claims 2
- 125000004499 isoxazol-5-yl group Chemical group O1N=CC=C1* 0.000 claims 2
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 2
- 239000003580 lung surfactant Substances 0.000 claims 2
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 claims 2
- 229960003073 pirfenidone Drugs 0.000 claims 2
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims 2
- 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 claims 2
- 229960004617 sapropterin Drugs 0.000 claims 2
- 239000000021 stimulant Substances 0.000 claims 2
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 235000019166 vitamin D Nutrition 0.000 claims 2
- 239000011710 vitamin D Substances 0.000 claims 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 2
- 229940046008 vitamin d Drugs 0.000 claims 2
- 125000004515 1,2,4-thiadiazol-3-yl group Chemical group S1N=C(N=C1)* 0.000 claims 1
- 125000004516 1,2,4-thiadiazol-5-yl group Chemical group S1N=CN=C1* 0.000 claims 1
- 125000004521 1,3,4-thiadiazol-2-yl group Chemical group S1C(=NN=C1)* 0.000 claims 1
- SUCDHPJUXCCMDN-UHFFFAOYSA-N 2-ethyl-1,3-oxazole Chemical group CCC1=NC=CO1 SUCDHPJUXCCMDN-UHFFFAOYSA-N 0.000 claims 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09179982.5 | 2009-12-18 | ||
| EP09179982 | 2009-12-18 | ||
| US31555210P | 2010-03-19 | 2010-03-19 | |
| US61/315,552 | 2010-03-19 | ||
| PCT/EP2010/069704 WO2011073231A1 (en) | 2009-12-18 | 2010-12-15 | 3,4,4A,10B-TETRAHYDRO-1H-THIOPYRANO-[4, 3-c] ISOQUINOLINE DERIVATIVES |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013514308A JP2013514308A (ja) | 2013-04-25 |
| JP2013514308A5 true JP2013514308A5 (OSRAM) | 2014-02-06 |
| JP5645961B2 JP5645961B2 (ja) | 2014-12-24 |
Family
ID=41718903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012543701A Expired - Fee Related JP5645961B2 (ja) | 2009-12-18 | 2010-12-15 | ３，４，４ａ，１０ｂ−テトラヒドロ−１Ｈ−チオピラノ−［４，３−ｃ］イソキノリン誘導体 |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US9018175B2 (OSRAM) |
| EP (2) | EP2513119B1 (OSRAM) |
| JP (1) | JP5645961B2 (OSRAM) |
| KR (1) | KR20120123313A (OSRAM) |
| CN (1) | CN102652136B (OSRAM) |
| AR (1) | AR079451A1 (OSRAM) |
| AU (1) | AU2010332955B8 (OSRAM) |
| BR (1) | BR112012014058A8 (OSRAM) |
| CA (1) | CA2784013A1 (OSRAM) |
| CO (1) | CO6551705A2 (OSRAM) |
| DK (1) | DK2513119T3 (OSRAM) |
| EA (1) | EA023212B1 (OSRAM) |
| ES (2) | ES2621291T3 (OSRAM) |
| GE (1) | GEP20146105B (OSRAM) |
| HR (1) | HRP20140893T1 (OSRAM) |
| ME (1) | ME01914B (OSRAM) |
| MX (1) | MX2012006696A (OSRAM) |
| NZ (1) | NZ601115A (OSRAM) |
| PH (1) | PH12012501125A1 (OSRAM) |
| PL (1) | PL2513119T3 (OSRAM) |
| PT (1) | PT2513119E (OSRAM) |
| RS (1) | RS53544B1 (OSRAM) |
| SG (2) | SG196785A1 (OSRAM) |
| SI (1) | SI2513119T1 (OSRAM) |
| SM (1) | SMT201400185B (OSRAM) |
| TW (1) | TWI468411B (OSRAM) |
| UA (1) | UA107689C2 (OSRAM) |
| WO (1) | WO2011073231A1 (OSRAM) |
| ZA (1) | ZA201204135B (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2577777B1 (en) | 2010-06-07 | 2016-12-28 | Sapurast Research LLC | Rechargeable, high-density electrochemical device |
| RU2013142268A (ru) * | 2011-02-17 | 2015-03-27 | Сипла Лимитед | Фармацевтическая композиция |
| EP2721036B1 (en) | 2011-06-15 | 2015-07-22 | Takeda GmbH | Novel 3,4,4a,10b-tetrahydro-1h-thiopyrano[4,3-c]isoquinoline compounds |
| WO2014016548A2 (en) * | 2012-07-27 | 2014-01-30 | Cipla Limited | Pharmaceutical composition |
| US20150322049A1 (en) * | 2012-12-13 | 2015-11-12 | Ludwig Aigner | Leukotriene pathway antagonists for the treatment of dementia, cognitive deficits in parkinson's disease and/or learning and memory deficiencies in parkinson's disease |
| EP2951161A1 (en) | 2013-02-04 | 2015-12-09 | Grünenthal GmbH | 4-amino substituted condensed pyrimidine compounds as pde4 inhibitors |
| MD20150071A2 (ro) | 2013-02-19 | 2016-02-29 | Pfizer Inc. | Compuşi azabenzimidazolici ca inhibitori ai PDE4 izoenzimelor pentru tratamentul tulburărilor SNC şi altor afecţiuni |
| US10131669B2 (en) | 2014-07-24 | 2018-11-20 | Pfizer Inc. | Pyrazolopyrimidine compounds |
| HUE044040T2 (hu) | 2014-08-06 | 2019-09-30 | Pfizer | Imidazopiridazin vegyületek |
| WO2017089347A1 (en) | 2015-11-25 | 2017-06-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas |
| US12383547B2 (en) | 2020-07-01 | 2025-08-12 | Vanderbilt University | Methods of treatment for a kidney disease |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3899494A (en) | 1970-05-13 | 1975-08-12 | Sandoz Ltd | Substituted 6-phenyl benzo-naphthyridines |
| DE2047465A1 (de) | 1970-09-26 | 1972-03-30 | Farbwerke Hoechst AG, vorm Meister Lucius & Bruning, 6000 Frankfurt | Neue Oxdiazole und Verfahren zu lh rer Herstellung |
| CN1003445B (zh) | 1984-10-03 | 1989-03-01 | 武田药品工业株式会社 | 噻唑烷二酮衍生物，其制备方法和用途 |
| JPH01213284A (ja) | 1988-02-22 | 1989-08-28 | Sankyo Co Ltd | チエノピリミジン−２，４−ジオン誘導体 |
| GB8828477D0 (en) | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
| DK0407028T4 (da) | 1989-05-31 | 2000-01-31 | Fisons Plc | Anordning til inhalation af medikamenter og sammensætning af medikamenter |
| GB8921222D0 (en) | 1989-09-20 | 1989-11-08 | Riker Laboratories Inc | Medicinal aerosol formulations |
| IE67185B1 (en) | 1990-02-02 | 1996-03-06 | Fisons Plc | Propellant compositions |
| DE4003272A1 (de) | 1990-02-03 | 1991-08-08 | Boehringer Ingelheim Kg | Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen |
| WO1991014422A1 (en) | 1990-03-23 | 1991-10-03 | Minnesota Mining And Manufacturing Company | The use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations |
| WO1992006675A1 (en) | 1990-10-18 | 1992-04-30 | Minnesota Mining And Manufacturing Company | Aerosol formulation comprising beclomethasone 17,21 dipropionate |
| AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
| IL104068A (en) | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant |
| GB9213874D0 (en) | 1992-06-30 | 1992-08-12 | Fisons Plc | Process to novel medicament form |
| GB9306703D0 (en) | 1993-03-31 | 1993-05-26 | Fisons Plc | Inhalation device |
| IL111194A (en) | 1993-10-08 | 1998-02-08 | Fisons Plc | Process for the production of medicament formulations |
| PL189641B1 (pl) | 1996-11-11 | 2005-09-30 | Altana Pharma Ag | Benzonaftyrydyny, środki farmaceutyczne je zawierające oraz zastosowanie benzonaftyrydyn |
| CA2288789C (en) | 1997-05-08 | 2009-07-21 | Merck Sharp & Dohme Limited | Substituted 1,2,4-triazolo[3,4-a]phthalazine derivatives as gaba alpha 5 ligands |
| AU8106598A (en) | 1997-06-03 | 1998-12-21 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Benzonaphthyridine |
| WO2000007567A1 (de) | 1998-08-04 | 2000-02-17 | Jago Research Ag | Medizinische aerosolformulierungen |
| US6397838B1 (en) | 1998-12-23 | 2002-06-04 | Battelle Pulmonary Therapeutics, Inc. | Pulmonary aerosol delivery device and method |
| WO2000064591A1 (en) | 1999-04-23 | 2000-11-02 | Battelle Memorial Institute | High mass transfer electrosprayer |
| BR0009993A (pt) | 1999-04-23 | 2002-01-08 | Battelle Memorial Institute | Pulverizador de aerossol eletrohidrodinâmico direcionalmente controlado, dispositivo para liberar gotìculas de aerossol eletricamente neutras, aparelho para liberar gotìculas de aerossol terapêuticas, processo para liberar gotìculas de aerossol, e, dispositivo para liberar aerossol |
| AU7961100A (en) | 1999-10-28 | 2001-05-08 | Daiichi Pharmaceutical Co., Ltd. | Drug discharge pump inhibitors |
| WO2001094350A1 (en) | 2000-06-07 | 2001-12-13 | Almirall Prodesfarma S.A. | 6-phenylpyrrolopyrimidinedione derivatives |
| WO2002005616A1 (en) | 2000-07-14 | 2002-01-24 | Altana Pharma Ag | Novel 6-phenylphenanthridines |
| CA2425035A1 (en) | 2000-10-09 | 2002-04-18 | 3M Innovative Properties Company | Medicinal aerosol formulations |
| JP2005504043A (ja) | 2001-08-10 | 2005-02-10 | パラチン テクノロジーズ インク． | 生物学的に活性な金属ペプチド類のペプチド模倣体類 |
| GB0202254D0 (en) | 2002-01-31 | 2002-03-20 | Pfizer Ltd | Prevention of scarring |
| US20030216407A1 (en) | 2002-01-31 | 2003-11-20 | Pfizer Inc. | Use of PDE5 inhibitors in the treatment of scarring |
| WO2004014916A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Pyrimidine fused bicyclic metalloproteinase inhibitors |
| EP1755589A4 (en) | 2004-04-23 | 2007-11-07 | Celgene Corp | METHOD OF USING PDE4 MODULATORS AND COMPOSITIONS COMPRISING THEM FOR THE TREATMENT AND MANAGEMENT OF PULMONARY HYPERTENSION |
| EP1791847A2 (en) | 2004-09-08 | 2007-06-06 | Altana Pharma AG | Novel 3-thia-10-aza-phenanthrene derivatives |
| DE602005027866D1 (de) * | 2004-09-08 | 2011-06-16 | Nycomed Gmbh | 3-oxa-10-aza-phenanthrene als pde4- oder pde3/4-inhibitoren |
| JP4943858B2 (ja) | 2004-11-17 | 2012-05-30 | キッセイ薬品工業株式会社 | 芳香族アミド誘導体、それを含有する医薬組成物およびそれらの医薬用途 |
| WO2006095009A1 (en) | 2005-03-09 | 2006-09-14 | Nycomed Gmbh | Amido-substituted 6-phenylphenanthridines |
| WO2008128647A1 (en) * | 2007-04-23 | 2008-10-30 | Sanofi-Aventis | Quinoline-carboxamide derivatives as p2y12 antagonists |
| EP2721036B1 (en) * | 2011-06-15 | 2015-07-22 | Takeda GmbH | Novel 3,4,4a,10b-tetrahydro-1h-thiopyrano[4,3-c]isoquinoline compounds |
-
2010
- 2010-12-14 AR ARP100104617A patent/AR079451A1/es unknown
- 2010-12-15 DK DK10790569.7T patent/DK2513119T3/da active
- 2010-12-15 BR BR112012014058A patent/BR112012014058A8/pt not_active IP Right Cessation
- 2010-12-15 US US13/515,214 patent/US9018175B2/en not_active Expired - Fee Related
- 2010-12-15 EP EP10790569.7A patent/EP2513119B1/en active Active
- 2010-12-15 JP JP2012543701A patent/JP5645961B2/ja not_active Expired - Fee Related
- 2010-12-15 AU AU2010332955A patent/AU2010332955B8/en not_active Ceased
- 2010-12-15 SI SI201030746T patent/SI2513119T1/sl unknown
- 2010-12-15 CN CN201080057293.7A patent/CN102652136B/zh not_active Expired - Fee Related
- 2010-12-15 MX MX2012006696A patent/MX2012006696A/es active IP Right Grant
- 2010-12-15 RS RSP20140499 patent/RS53544B1/sr unknown
- 2010-12-15 PT PT107905697T patent/PT2513119E/pt unknown
- 2010-12-15 PL PL10790569T patent/PL2513119T3/pl unknown
- 2010-12-15 SG SG2014000335A patent/SG196785A1/en unknown
- 2010-12-15 ES ES14164018.5T patent/ES2621291T3/es active Active
- 2010-12-15 UA UAA201208482A patent/UA107689C2/ru unknown
- 2010-12-15 EA EA201200891A patent/EA023212B1/ru not_active IP Right Cessation
- 2010-12-15 CA CA2784013A patent/CA2784013A1/en not_active Abandoned
- 2010-12-15 NZ NZ601115A patent/NZ601115A/en not_active IP Right Cessation
- 2010-12-15 KR KR1020127017957A patent/KR20120123313A/ko not_active Withdrawn
- 2010-12-15 ME MEP-2014-114A patent/ME01914B/me unknown
- 2010-12-15 PH PH1/2012/501125A patent/PH12012501125A1/en unknown
- 2010-12-15 EP EP14164018.5A patent/EP2813509B1/en active Active
- 2010-12-15 GE GEAP201012783A patent/GEP20146105B/en unknown
- 2010-12-15 WO PCT/EP2010/069704 patent/WO2011073231A1/en not_active Ceased
- 2010-12-15 SG SG2012034732A patent/SG180824A1/en unknown
- 2010-12-15 HR HRP20140893AT patent/HRP20140893T1/hr unknown
- 2010-12-15 ES ES10790569.7T patent/ES2505290T3/es active Active
- 2010-12-17 TW TW99144591A patent/TWI468411B/zh not_active IP Right Cessation
-
2012
- 2012-05-24 CO CO12085785A patent/CO6551705A2/es active IP Right Grant
- 2012-06-06 ZA ZA2012/04135A patent/ZA201204135B/en unknown
-
2014
- 2014-12-11 SM SM201400185T patent/SMT201400185B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013514308A5 (OSRAM) | ||
| HRP20140893T1 (hr) | Derivati 3,4,4a,10b-tetrahidro-1h-tiopirano-[4,3-c]izokinolina | |
| RU2352568C2 (ru) | [1,2,4]оксадиазолы (варианты), способ их получения, фармацевтическая композиция и способ ингибирования активации метаботропных глютаматных рецепторов-5 | |
| AU2010204118B2 (en) | Sulfonamide derivatives | |
| JP2015533157A5 (OSRAM) | ||
| US8420655B2 (en) | Benzimidazole inhibitors of leukotriene production | |
| JP2014525444A5 (OSRAM) | ||
| US9174980B2 (en) | Heterocyclic compounds as inhibitors of leukotriene production | |
| JP2009526081A5 (OSRAM) | ||
| JP2018535999A5 (OSRAM) | ||
| JP2007523208A5 (OSRAM) | ||
| JP2019517455A5 (OSRAM) | ||
| JP2013517281A5 (OSRAM) | ||
| IL303196A (en) | Heteroaryl-substituted pyridines and methods of use | |
| US8367679B2 (en) | Biaryl carboxamides | |
| JP2013512910A5 (OSRAM) | ||
| HRP20120281T1 (hr) | Derivati azabiciklo[3.1.0]heksana, korisni kao modulatori dopaminskih receptora d3 | |
| JP2006502134A5 (OSRAM) | ||
| JP2010526106A5 (OSRAM) | ||
| JP2013517278A5 (OSRAM) | ||
| JP2020520354A5 (OSRAM) | ||
| JP2017532364A5 (OSRAM) | ||
| JP2020520358A5 (OSRAM) | ||
| JP2015517580A5 (OSRAM) | ||
| JP4465195B2 (ja) | 新規化合物 |